top of page

“Let’s aim for helping people to live much longer than we can today. And if we only end up helping them live really well for a long time that will be great too.”
- Andrew Worden


Our Mission

Lifespan Vision Ventures invests in companies that develop therapeutics focusing on longevity and aging reversal. 

​Our goal is to enable healthy, strong, and vibrant human lifespan past 120 years.

Our primary foci are the whole body, joints, heart, skin, brain, and muscles.


Value Add

  • Deep understanding of science and technology. 

  • Ability to lead or participate in founding, seed, angel, early and mid-stage investment rounds.

  • Strong financial market contacts for obtaining working capital needed through bank lines, follow on equity and debt financings and public offerings.

  • Management has proven entrepreneurial business ability to found and lead startups that demonstrate rapid and successful growth.

  • Relationships with a wide variety of academics, professionals, and institutions allow LifeSpan to bring parties together for collaboration and to create synergy between these different parties. This can accelerate development timelines and allow for new possibilities to be uncovered.

Our Founding Partner, Visionary:
Andrew Worden

Connecticut, United States



Through his business ventures, Mr. Worden has gained unique insights on how to scale businesses rapidly and successfully.  He has decades of experience in launching, managing, planning, analyzing, and investing with public and private companies, especially within the cleantech markets. Mr. Worden has a proven combination of understanding science, technology, and entrepreneurship.

Mr. Worden founded GameChange Solar in 2012 with the vision to make solar energy become the lowest cost technology for electricity generation globally. His leadership and experience led to GameChange Solar’s growth in improving technology and leveraging massive scale manufacturing to aggressively cost reduce its systems and substantially reduce the total cost of solar power plants. GameChange Solar has grown from a startup in 2012 to become a global leader with over $1 billion in profitable sales in 2022. Solar energy is now among the lowest cost for electricity generation in most world markets.

In 2010, prior to GameChange Solar, Mr. Worden founded Soltas Energy to develop and own solar power plants. The company built ten solar power plants which were then successfully sold by 2014.

Prior to 2010, Mr. Worden has decades of experience as an investor primarily with Barron Partners LP, which was a global long-only investment partnership. While managing Barron Partners LP, Mr. Worden oversaw investments in over 170 companies globally in multiple industries. Many of these companies were either public or private companies which later became public. The investments in each company ranged up to $15 million individually.


Mr. Worden was the General Partner of Barron and ultimately became the largest investor of the company. He changed his primary focus from investments to renewable energy starting with Soltas Energy and then with GameChange Solar.

In addition, Mr. Worden is the founder and serves as a director of the Barron Charitable Foundation, a non-profit organization dedicated to helping those in need.

To further his vision for longevity, Mr. Worden has established and funded research at Harvard University’s John A. Paulson School of Engineering and Applied Sciences. The Andrew Worden SEAS Dean’s Innovation Fund is dedicated to funding scientific research in cleantech, AI, medical, and other key areas.


Birthplace: Boston, Massachusetts
Education: Graduated from Harvard University with a Bachelor of Arts Degree in Physical Sciences. As a cross-enrolled undergraduate while at Harvard, Mr. Worden also studied Engineering at the Massachusetts Institute of Technology in conjunction with Finance and Marketing at MIT’s Sloan School of Business.


Harry Robb


London, England

Mr. Robb is a member of the investment team at LifeSpan Vision Ventures and brings hands-on experience in conducting comprehensive research and analysis to facilitate investment decision-making across the longevity biotech sector.


Previously, Mr. Robb served as an investment manager at Longevity.Technology, a media and investment platform dedicated to the longevity sector. In this role, he established Longevity.Technology’s global institutional and private client investor network, and oversaw deal origination, culminating in the development of a deal pipeline with an estimated value of $300 million.

While pursuing his Master of Science Degree at Imperial College London, Mr. Robb was an intern at FLYFWD Ventures and OXWASH. At FLYFWD Ventures, he assumed an investment role, while at OXWASH, he contributed to business development efforts in the field of sustainable laundry services.

Birthplace: Preston, United Kingdom
Education: Graduated from Imperial College London with a Master of Science Degree in Applied Biosciences and Biotechnology, and from King’s College London with a Bachelor of Science Degree in Biomedical Science.

Harry Robb .jpg

Jordan B. Burton, Ph.D

Scientific Analyst

California, United States

Dr. Burton is a vital part of the investment team at LifeSpan Vision Ventures. Driven by his passion for the intersection of science and business, he leverages his strong research background and analytical skills to facilitate the development of translational research from the lab bench to the clinic. His post-doctoral work at the Buck Institute for Research on Aging focuses on the identification of biomarker candidates and the development of innovative interventions for age-related diseases.
With over 10 co-authored peer-reviewed publications to his name, Dr. Burton's expertise is invaluable in the investment decision-making process, particularly within the longevity biotech sector. His hands-on experience in conducting scientific research and data analysis allows him to meticulously evaluate potential technologies for their scientific merit and market potential.

Dr. Burton's journey into the world of biotech investments was paved during his time at Wayne State University. While pursuing his Ph.D. in Chemistry, he was part of the Innovation Honors Program, which gave him a solid foundation in technology transfer – the process of turning lab discoveries into viable clinical treatments. His dissertation, "Extending Plasma Proteome Coverage to Enable Biomarker Discovery", exemplifies his commitment to bridging the gap between research and practical application in healthcare.

Birthplace: Sault Ste. Marie, Michigan
Education: Graduated from Wayne State University with a Doctorate in Analytical Chemistry, and Lake Superior State University with a Bachelor of Science Degree in Chemistry.

bottom of page